CMS denies coverage for Menaflex
This article was originally published in The Gray Sheet
Executive Summary
Medicare agency issues national non-coverage decision May 25 for ReGen Biologics' Menaflex collagen knee meniscus implant, in-line with a February CMS proposal concluding the device did not improve health outcomes and is therefore not reasonable and necessary (1"The Gray Sheet" March 1, 2010). FDA is expected to conclude a re-review of preclinical and clinical data used to support Menaflex' 510(k) clearance within the next few weeks (2"The Gray Sheet" March 29, 2010)
You may also be interested in...
With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks
FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week
Medicare In Brief
LVAD coverage analysis: CMS will consider whether to expand national Medicare coverage for ventricular assist device destination therapy to match recently updated FDA labeling for Thoratec's HeartMate II, the agency said Feb. 22. The coverage analysis was opened in response to a request by Thoratec, which gained PMA approval in January for its next-generation left-ventricular-assist device to keep alive end-stage heart failure patients who are not candidates for transplant (1"The Gray Sheet" Jan. 25, 2010). The FDA-indicated destination therapy population for HeartMate II includes a broader set of heart failure patients and a lower duration requirement for prior failed therapies than what was approved for Thoratec's older-generation HeartMate XVE, the device that formed the basis of the current Medicare destination therapy coverage policy established in 2003. CMS will issue a proposal by August 22 on whether to expand coverage and a final decision by Nov. 20. Comments are due March 24
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.